Abstract:Dominant optic atrophy (DOA) is an inherited mitochondrial disease leading to specific degeneration of retinal ganglion cells (RGCs), thus compromising transmission of visual information from the retina to the brain. Usually, DOA starts during childhood and evolves to poor vision or legal blindness, affecting the central vision, whilst sparing the peripheral visual field. In 20% of cases, DOA presents as syndromic disorder, with secondary symptoms affecting neuronal and muscular functions. Twenty years ago, we demonstrated that heterozygous mutations in OPA1 are the most frequent molecular cause of DOA. Since then, variants in additional genes, whose functions in many instances converge with those of OPA1, have been identified by next generation sequencing. OPA1 encodes a dynamin-related GTPase imported into mitochondria and located to the inner membrane and intermembrane space. The many OPA1 isoforms, resulting from alternative splicing of three exons, form complex homopolymers that structure mitochondrial cristae, and contribute to fusion of the outer membrane, thus shaping the whole mitochondrial network. Moreover, OPA1 is required for oxidative phosphorylation, maintenance of mitochondrial genome, calcium homeostasis and regulation of apoptosis, thus making OPA1 the Swiss army-knife of mitochondria. Understanding DOA pathophysiology requires the understanding of RGC peculiarities with respect to OPA1 functions. Besides the tremendous energy requirements of RGCs to relay visual information from the eye to the brain, these neurons present unique features related to their differential environments in the retina, and to the anatomical transition occurring at the lamina cribrosa, which parallel major adaptations of mitochondrial physiology and shape, in the pre- and post-laminar segments of the optic nerve. Three DOA mouse models, with different Opa1 mutations, have been generated to study intrinsic mechanisms responsible for RGC degeneration, and these have further revealed secondary symptoms related to mitochondrial dysfunctions, mirroring the more severe syndromic phenotypes seen in a subgroup of patients. Metabolomics analyses of cells, mouse organs and patient plasma mutated for OPA1 revealed new unexpected pathophysiological mechanisms related to mitochondrial dysfunction, and biomarkers correlated quantitatively to the severity of the disease. Here, we review and synthesize these data, and propose different approaches for embracing possible therapies to fulfil the unmet clinical needs of this disease, and provide hope to affected DOA patients.

OPA 1 mutation affects autophagy and triggers senescence in autosomal dominant optic atrophy plus fibroblasts

The Molecular Pathogenesis of Autosomal Dominant Optic Atrophy

A Novel OPA1 Mutation in a Chinese Family with Autosomal Dominant Optic Atrophy

OPA1 and disease-causing mutants perturb mitochondrial nucleoid distribution

OPA1 Modulates Mitochondrial Ca2+ Uptake Through ER-Mitochondria Coupling

Modeling Autosomal Dominant Optic Atrophy Using Induced Pluripotent Stem Cells and Identifying Potential Therapeutic Targets.

A Novel Adoa-Associated Opa1 Mutation Alters the Mitochondrial Function, Membrane Potential, Ros Production and Apoptosis

and disease-causing mutants perturb mitochondrial nucleoid distribution

Dominant optic atrophy: Culprit mitochondria in the optic nerve

Assocation Between Leber's Hereditary Optic Neuropathy and MT-ND1 3460G>A Mutation-Induced Alterations in Mitochondrial Function, Apoptosis, and Mitophagy.

Opa1 Haploinsufficiency Due To A Novel Splicing Variant Resulting In Mitochondrial Dysfunction Without Mitochondrial Dna Depletion

Syndromic parkinsonism and dementia associated with OPA 1 missense mutations

The molecular mechanisms of OPA1-mediated optic atrophy in Drosophila model and prospects for antioxidant treatment

The human OPA1delTTAG mutation induces adult onset and progressive auditory neuropathy in mice

Drosophila model to clarify the pathological significance of OPA1 in autosomal dominant optic atrophy

Processing of OPA1 with a novel N-terminal mutation in patients with autosomal dominant optic atrophy: Escape from nonsense-mediated decay

model to clarify the pathological significance of OPA1 in autosomal dominant optic atrophy

Creation of an Isogenic Human iPSC-Based RGC Model of Dominant Optic Atrophy Harboring the Pathogenic Variant c.1861C>T (p.Gln621Ter) in the OPA1 Gene

AFG3L2 and ACO2-linked Dominant Optic Atrophy: genotype-phenotype characterization compared to OPA1 patients

Loss of SARM1 protects against retinal ganglion cell degeneration in Autosomal Dominant Optic Atrophy

Targeting DRP1 with Mdivi-1 to Correct Mitochondrial Abnormalities in ADOA Plus Syndrome